Higher Plasma Levels of Endocannabinoids and Analogues Correlate With a Worse Cardiometabolic Profile in Young Adults
Metadatos
Afficher la notice complèteAuteur
Di, Xinyu; Martínez Téllez, Borja Manuel; Krekels, Elke H.J.; Jurado Fasoli, Lucas; Osuna Prieto, Francisco Javier; Ortiz Álvarez, Lourdes; Hankemeier, Thomas; Rensen, Patrick C. N.; Ruiz Ruiz, Jonatan; Kohler, IsabelleEditorial
Oxford University Press
Materia
Body composition Cardiometabolic risk factors Anandamide
Date
2023-11-15Referencia bibliográfica
The Journal of Clinical Endocrinology & Metabolism, 2023, 00, 1–10 [10.1210/clinem/dgad668]
Patrocinador
Spanish Ministry of Economy and Competitiveness via the Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI13/01393); Spanish Ministry of Economy and Competitiveness (PTA-12264); Retos de la Sociedad (DEP2016-79512-R); European Regional Development Fund (ERDF); Spanish Ministry of Education (FPU16/02828, FPU17/01523 and FPU19/01609); Fundación Iberoamericana de Nutrición (FINUT); Redes Temáticas de Investigación Cooperativa RETIC (Red SAMID RD16/0022); AstraZeneca HealthCare Foundation; University of Granada Plan Propio de Investigación 2016 -Excellence actions: Unit of Excellence on Exercise and Health (UCEES); Junta de Andalucía, Consejería de Conocimiento, Investigación y Universidades (ERDF; ref. SOMM17/6107/UGR and DOC 01151); Fundación Alfonso Martin Escudero; Dutch Heart Foundation, Dutch Federation of University Medical Centers; Netherlands Organization for Health Research and Development; Royal Netherlands Academy of Arts and Sciences (CVON2017-20 GENIUS-2); China Scholarship Council (no. 201707060012)Résumé
Context: The endocannabinoid system (ECS) is a signaling system composed of endocannabinoids (eCBs), their receptors, and the enzymes
involved in their synthesis and metabolism. Alterations in the ECS are linked to the development of cardiometabolic diseases.
Objective: Here, we investigated the relationship between plasma levels of eCBs and their analogues with body composition and
cardiometabolic risk factors.
Methods: The study included 133 young adults (age 22.1 ± 2.2 years, 67% women). Fasting plasma levels of eCBs and their analogues were
measured using liquid chromatography-tandem mass spectrometry. Body composition, brown adipose tissue (BAT) volume, glucose uptake,
and traditional cardiometabolic risk factors were measured.
Results: Plasma levels of eCBs and several eCB analogues were positively correlated with adiposity and traditional cardiometabolic risk factors (eg,
serum insulin and triacylglyceride levels, all r ≥ 0.17 and P ≤ .045). Plasma levels of 2-arachidonoyl glycerol and N-pentadecenoylethanolamine were
negatively correlated with BAT volume and glucose uptake (all r ≤ −0.17 and P ≤ .047). We observed that the plasma levels of eCBs and their
analogues were higher in metabolically unhealthy overweight–obese participants than in metabolically healthy overweight–obese participants.
Conclusion: Our findings show that the plasma levels of eCBs and their analogues are related to higher levels of adiposity and worse
cardiometabolic profile.